Back to School: How biopharma can reboot drug development. Access exclusive analysis here
INDICATION: Brain cancer
Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury